At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,415 enrolled
Drug / intervention
Rimegepant 75mg daily dosing +2 moredrug
Likely dose
Rimegepant 75mg daily dosingfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
In Brief
A Phase 4 clinical trial evaluating Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, and 1 other intervention for Migraine. Completed, enrolled 1,415 participants across 107 sites in 10 countries.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesAustria, Canada, France, Germany, Italy, Poland, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionOct 2024
Study CompletionDec 2024
TodayJul 2026
First PostedFeb 1, 2022
Enrollment StartMar 4, 2022
Primary CompletionOct 22, 2024
Study CompletionDec 11, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.4 years ago
Interventions
Rimegepant 75mg daily dosingdrug
Daily
Rimegepant 75mg every other day dosingdrug
Every other day
Placebo comparator dosingdrug
Placebo comparator